{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:51:32Z","timestamp":1760057492788,"version":"build-2065373602"},"reference-count":29,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epidemiologia"],"abstract":"<jats:p>Background: HIV-related opportunistic infections like Pneumocystis jirovecii Pneumonia (PCP) remain a major contributor to child morbidity and mortality globally. PCP accounts for over 60% of AIDS in the first year of life and is responsible for a third of AIDS in children globally. Cotrimoxazole prophylaxis, which is an intervention directed towards tackling this burden, has not attained remarkable coverage despite advocacy towards scale-up. This work was therefore aimed at evaluating the efficacy of cotrimoxazole in the prevention of PCP among children exposed to and infected with HIV by carrying out a systematic review. Methods: Key scientific databases were searched for primary studies not older than 15 years old without language restrictions. Randomized Control Trials (RCTs) and Cohorts comparing the effectiveness of cotrimoxazole versus placebo in the prevention of PCP among children (&lt;17 years) exposed to and infected with HIV were selected. Studies with a duration of follow-up not less than 3 months long were included. A meta-analysis was conducted on RevMan 5.3 statistical application software following data extraction, and the data quality and risk of bias were also assessed. Exactly Ten (10) studies were selected and analyzed. Findings: It was observed that cotrimoxazole had beneficial effects in terms of a reduction in mortality among HIV-exposed and infected children, as 72 fewer children in 1000 (based on an absolute 95% CI) will die as a result of cotrimoxazole compared to a placebo. Cotrimoxazole also significantly reduces hospital admissions (p-value of 0.008). The adverse events associated with cotrimoxazole are comparable to a placebo when co-administered with ARTS (p = 0.90), which did not impact adherence. Conclusion: The benefits of cotrimoxazole prophylaxis far outweigh its risks. Therefore, scaling up the intervention is recommended as a prophylactic for wider coverage, especially in resource-limited settings.<\/jats:p>","DOI":"10.3390\/epidemiologia6010008","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T08:01:19Z","timestamp":1739433679000},"page":"8","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Efficacy of Cotrimoxazole for the Prevention of Pneumocystis\u00a0jirovecii Pneumonia Among HIV-Exposed and Infected Children: A Systematic Review"],"prefix":"10.3390","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5227-743X","authenticated-orcid":false,"given":"Anthony O.","family":"Agwu","sequence":"first","affiliation":[{"name":"Department of Public Health, University of Chester, Chester CH1 4BJ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3408-5471","authenticated-orcid":false,"given":"Chinedu Ogbonnia","family":"Egwu","sequence":"additional","affiliation":[{"name":"Medical Biochemistry Department, College of Medicine, Alex-Ekwueme Federal University Ndufu-Alike, P.M.B. 1010, Ikwo 482131, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert Egwu","family":"Okorocha","sequence":"additional","affiliation":[{"name":"Physiology Department, College of Medicine, Alex-Ekwueme Federal University Ndufu-Alike, P.M.B. 1010, Ikwo 482131, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ifeanyi","family":"Enyanwuma","sequence":"additional","affiliation":[{"name":"Surgery Department, Alex Ekwueme Federal University Teaching Hospital, Abakaliki 480282, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyril C.","family":"Amadi","sequence":"additional","affiliation":[{"name":"Medical Biochemistry Department, College of Medicine, Alex-Ekwueme Federal University Ndufu-Alike, P.M.B. 1010, Ikwo 482131, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3219-5995","authenticated-orcid":false,"given":"Evaezi","family":"Okpokoro","sequence":"additional","affiliation":[{"name":"International Research Center of Excellence, Institute of Human Virology, Abuja 900246, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis Patrick","family":"Akpabio","sequence":"additional","affiliation":[{"name":"Garki Hospital, Tafawa Balewa Way, Area 8, Garki, Abuja 900103, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chukwuemeka Ogbonnaya","family":"Aguwa","sequence":"additional","affiliation":[{"name":"Overcomer Jubilee Hospital, Umuahia 440221, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatus","family":"Onwu","sequence":"additional","affiliation":[{"name":"Orthopedics Department, Alex Ekwueme Federal University Teaching Hospital, Abakaliki 480282, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onyedikachi","family":"Nwokoro","sequence":"additional","affiliation":[{"name":"Surgery Department, Alex Ekwueme Federal University Teaching Hospital, Abakaliki 480282, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"ref_1","unstructured":"(2024, October 02). WHO Why the HIV Epidemic Is Not Over. Available online: https:\/\/www.who.int\/news-room\/spotlight\/why-the-hiv-epidemic-is-not-over."},{"key":"ref_2","unstructured":"Vaillant, A.A.J., and Naik, R. (2023). HIV-1\u2013Associated Opportunistic Infections, StatPearls."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.ijtb.2023.09.002","article-title":"The \u2018Pulmonary Diseases Spectrum\u2019 in HIV Infected Children","volume":"70","author":"Lala","year":"2023","journal-title":"Indian J. Tuberc."},{"key":"ref_4","first-page":"820","article-title":"Prevention of HIV-Associated Respiratory Illness in Children in Developing Countries: Potential Benefits","volume":"7","author":"Zar","year":"2003","journal-title":"Int. J. Tuberc. Lung Dis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1513\/pats.201009-062WR","article-title":"HIV-Associated Pneumocystis Pneumonia","volume":"8","author":"Huang","year":"2011","journal-title":"Proc. Am. Thorac. Soc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1097\/00002030-200007280-00012","article-title":"Evaluating a New Strategy for Prophylaxis to Prevent Pneumocystis Carinii Pneumonia in HIV-Exposed Infants in Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group","volume":"14","author":"Chokephaibulkit","year":"2000","journal-title":"AIDS"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.spid.2005.06.008","article-title":"Perinatally Acquired HIV-1 Infection: Prevention and Evaluation of HIV-Exposed Infants","volume":"16","author":"Shetty","year":"2005","journal-title":"Semin. Pediatr. Infect. Dis."},{"key":"ref_8","first-page":"890","article-title":"Childhood Pneumonia - Progress and Challenges","volume":"96","author":"Zar","year":"2006","journal-title":"South African Med. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1473-3099(07)70239-6","article-title":"Scaling-up Co-Trimoxazole Prophylaxis in HIV-Exposed and HIV-Infected Children in High HIV-Prevalence Countries","volume":"7","author":"Zachariah","year":"2007","journal-title":"Lancet. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e26079","DOI":"10.1002\/jia2.26079","article-title":"Co-trimoxazole Prophylaxis for Children Who Are HIV-exposed and Uninfected: A Systematic Review","volume":"26","author":"Wedderburn","year":"2023","journal-title":"J. Int. AIDS Soc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1473-3099(14)71011-4","article-title":"The Expanding Role of Co-Trimoxazole in Developing Countries","volume":"15","author":"Church","year":"2015","journal-title":"Lancet. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/S0140-6736(04)17442-4","article-title":"Co-Trimoxazole as Prophylaxis against Opportunistic Infections in HIV-Infected Zambian Children (CHAP): A Double-Blind Randomised Placebo-Controlled Trial","volume":"364","author":"Chintu","year":"2004","journal-title":"Lancet"},{"key":"ref_13","unstructured":"Higgins, J., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M., and Welch, V. (2024, October 01). Cochrane Handbook for Systematic Reviews of Interventions|Cochrane Training. Available online: https:\/\/training.cochrane.org\/handbook."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/0003-4819-134-8-200104170-00012","article-title":"The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration","volume":"134","author":"Lepage","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1214901","article-title":"A Randomized Trial of Prolonged Co-Trimoxazole in HIV-Infected Children in Africa","volume":"370","author":"Kendall","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0022-3476(05)83301-3","article-title":"Efficacy of Primary Chemoprophylaxis against Pneumocystis Carinii Pneumonia during the First Year of Life in Infants Infected with Human Immunodeficiency Virus Type 1","volume":"125","author":"Rigaud","year":"1994","journal-title":"J. Pediatr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e727","DOI":"10.1016\/S2214-109X(14)70329-8","article-title":"Protective Efficacy of Prolonged Co-Trimoxazole Prophylaxis in HIV-Exposed Children up to Age 4 Years for the Prevention of Malaria in Uganda: A Randomised Controlled Open-Label Trial","volume":"2","author":"Homsy","year":"2014","journal-title":"Lancet Glob. Heal."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/QAD.0b013e32835ca29f","article-title":"Health Outcomes of HIV-Exposed Uninfected African Infants","volume":"27","author":"Kourtis","year":"2013","journal-title":"AIDS"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1086\/343049","article-title":"Ineffectiveness of Trimethoprim-Sulfamethoxazole Prophylaxis and the Importance of Bacterial and Viral Coinfections in African Children with Pneumocystis Carinii Pneumonia","volume":"35","author":"Madhi","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1542\/peds.97.1.59","article-title":"Benefit of Primary Prophylaxis before 18 Months of Age in Reducing the Incidence of Pneumocystis Carinii Pneumonia and Early Death in a Cohort of 112 Human Immunodeficiency Virus-Infected Infants. New York City Perinatal HIV Transmission Collaborative Stu","volume":"97","author":"Thea","year":"1996","journal-title":"Pediatrics"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10461-008-9382-4","article-title":"Adherence to Both Cotrimoxazole and Placebo Is Associated with Improved Survival among HIV-Infected Zambian Children","volume":"13","author":"Walker","year":"2009","journal-title":"AIDS Behav."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1016\/S2214-109X(16)30096-1","article-title":"Daily Co-Trimoxazole Prophylaxis to Prevent Mortality in Children with Complicated Severe Acute Malnutrition: A Multicentre, Double-Blind, Randomised Placebo-Controlled Trial","volume":"4","author":"Berkley","year":"2016","journal-title":"Lancet Glob. Heal."},{"key":"ref_24","unstructured":"WHO (2006). Guidelines on Co-Trimoxazole Prophylaxis for HIV-Related Infections among Children, Adolescents and Adults: Recommendations for a Public Health Approach, WHO Press."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/S0140-6736(02)11921-0","article-title":"Prophylaxis against Pneumocystis Carinii Pneumonia for HIV-Exposed Infants in Africa","volume":"360","author":"Graham","year":"2002","journal-title":"Lancet"},{"key":"ref_26","first-page":"CD003108","article-title":"Cotrimoxazole Prophylaxis for Opportunistic Infections in Adults with HIV","volume":"2003","author":"Grimwade","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e1198","DOI":"10.1016\/S2214-109X(22)00120-6","article-title":"Cotrimoxazole Guidelines for Infants Who Are HIV-Exposed but Uninfected: A Call for a Public Health and Ethics Approach to the Evidence","volume":"10","author":"Daniels","year":"2022","journal-title":"Lancet. Glob. Heal."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1111\/bcp.13397","article-title":"Suboptimal Cotrimoxazole Prophylactic Concentrations in HIV-Infected Children According to the WHO Guidelines","volume":"83","author":"Pressiat","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1016\/S2352-3018(15)00137-X","article-title":"Causes of Hospital Admission among People Living with HIV Worldwide: A Systematic Review and Meta-Analysis","volume":"2","author":"Ford","year":"2015","journal-title":"Lancet HIV"}],"container-title":["Epidemiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2673-3986\/6\/1\/8\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:32:29Z","timestamp":1760027549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2673-3986\/6\/1\/8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["epidemiologia6010008"],"URL":"https:\/\/doi.org\/10.3390\/epidemiologia6010008","relation":{},"ISSN":["2673-3986"],"issn-type":[{"type":"electronic","value":"2673-3986"}],"subject":[],"published":{"date-parts":[[2025,2,13]]}}}